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Abstract: Despite numerous studies on women’s cardiac health throughout the past decade, the
number of female deaths caused by cardiovascular disease still rises and remains the leading cause
of death in women in most areas of the world. Novel studies have demonstrated that cardiovascular
disease, and more specifically coronary artery disease presentations in women, are different than
those in men. In addition, pathology and pathophysiology of the disease present significant
gender differences, which leads to difficulties concerning diagnosis, treatment and outcome of the
female population. The reason for this disparity is all steps for female cardiovascular disease
evaluation, treatment and prevention are not well elucidated; and an area for future research. This
review brings together the most recent studies published in the field of coronary artery disease
in women and points out new directions for future investigation on some of the important issues.
Keywords: coronary artery disease, women, risk factors, prevention, diagnosis, treatment.
Introduction
The first female-specific recommendations for preventive cardiology were published in
1999 (Mosca et al 1999). Even though research in the treatment of cardiovascular disease
(CVD) had advanced in many areas, it remains the leading cause of death in women in
most parts of the world. Studies have shown that 500 thousand women die of CVD every
year in the United States, somewhat near one death every minute (American Heart
Association 2003). Such index exceeds not only the number of deaths in men, but also the
next seven causes of death in women combined, and more importantly, coronary artery
disease (CAD) is believed to be the major cause responsible for these deaths (American
Heart Association 2003). Over a quarter of a million deaths per year are attributed to CAD
alone in the United States (Merz et al 2004). Although already high, these figures are
expected to rise even more during the next decades, due to an increase of diabetes and
obesity, as well as the aging of the world population (Merz et al 2004).
Even though women have a higher frequency of chest pain/angina than men, the
incidence of obstructive CAD in the female population is lower when compared with
men with similar symptoms (Kenedy et al 1982; Diamond et al 1983; Merz et al 1999). In
addition, it would appear that young women with obstructive CAD have a worse
prognosis after acute myocardial infarction (AMI), whereas older women in similar
circumstances often present with larger number of comorbidities that adversely influence
the outcome, when compared to men (Coronado et al 1997). Women with acute coronary
syndromes (ACS) are also less likely to receive rapid effective diagnosis and treatment
than are men (Ayanian and Epstein 1991; Maynard et al 1996; Pope
et al 2000).
Regarding the North American population, the Women’s Ischemic Syndrome
Evaluation (WISE) study workshop (Hayes et al 2004; Maseri 2004; Nabel et al 2004;
Pepine et al 2004; Shaw et al 2004; Waters et al 2004) from the National Heart, Lung and
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Abstract: Over the past decade, 17 large placebo-controlled trials have established that statin 
therapy lowers LDL cholesterol and prevents cardiovascular events and death in patients with 
coronary disease or at high risk for atherosclerotic events. Nine trials of higher dose vs. lower 
dose statins (reporting data from 29,853 patients with coronary artery disease and 486 patients 
with other indications for statin therapy) have established that higher dose statin therapy is more 
efﬁ  cacious than lower dose therapy in reducing myocardial infarctions/coronary death (by 16%) 
and stroke (by 18%) in patients with coronary disease but only reduces all-cause mortality in 
patients at high risk for coronary death (such as patients immediately after acute coronary 
syndrome). Higher dose statins are associated with statistically signiﬁ  cantly increased risks of 
myopathy and elevated transaminases compared to lower dose statins; while relative risks for 
these outcomes are 1.2 and 4.0, the absolute increases are small (0.5% and 1%). Secondary 
analyses of these trials using individual patient data and multivariate adjustment will be needed 
to appropriately examine the incremental beneﬁ  ts of different LDL targets, and trials are needed 
to determine whether combinations of low dose statins plus other lipid lowering agents may 
achieve better clinical outcomes than higher dose statin therapy alone. 
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Over the past decade, an impressive number of randomized trials have conﬁ  rmed 
that treatment with statins prevents cardiovascular events and improves survival in 
patients with a history of cardiovascular events as well as in patients who have not 
yet had an event but are at increased risk due to elevated cholesterol levels, diabetes 
mellitus, or hypertension (Law et al 2003; Cholesterol Treatment Trialists 2005). As a 
result of this randomized trial evidence, the indications for statin drugs have expanded 
rapidly and current guidelines recommend statin use in patients with, or at high risk 
for, atherosclerosis (Grundy et al 2004; Joint British Societies 2005; Khan et al 2006). 
Although meta-regression analyses of these randomized trials have conﬁ  rmed that 
statins appear to exert their beneﬁ  cial effects primarily via reduction of LDL cholesterol 
levels (Robinson et al 2005), the target LDL for patients with coronary artery disease 
(CAD) has remained a point of debate as this evidence base has accumulated. 
Although large observational studies consistently demonstrate a strong log-linear 
relationship between blood cholesterol levels and coronary mortality (Verschuren 
et al 1995; Padwal et al 2001), these studies have not identiﬁ  ed a threshold level for 
LDL cholesterol which separates those who will suffer a coronary event from those 
who will not (Chen et al 1991; O’Keefe 2004). While the cardiovascular relative risk 
reductions achieved with statin therapy appear to be similar regardless of baseline 
cholesterol levels in the large placebo-controlled randomized trials published thus Vascular Health and Risk Management 2006:2(4) 465–475
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Introduction
The first female-specific recommendations for preventive cardiology were published in
1999 (Mosca et al 1999). Even though research in the treatment of cardiovascular disease
(CVD) had advanced in many areas, it remains the leading cause of death in women in
most parts of the world. Studies have shown that 500 thousand women die of CVD every
year in the United States, somewhat near one death every minute (American Heart
Association 2003). Such index exceeds not only the number of deaths in men, but also the
next seven causes of death in women combined, and more importantly, coronary artery
disease (CAD) is believed to be the major cause responsible for these deaths (American
Heart Association 2003). Over a quarter of a million deaths per year are attributed to CAD
alone in the United States (Merz et al 2004). Although already high, these figures are
expected to rise even more during the next decades, due to an increase of diabetes and
obesity, as well as the aging of the world population (Merz et al 2004).
Even though women have a higher frequency of chest pain/angina than men, the
incidence of obstructive CAD in the female population is lower when compared with
men with similar symptoms (Kenedy et al 1982; Diamond et al 1983; Merz et al 1999). In
addition, it would appear that young women with obstructive CAD have a worse
prognosis after acute myocardial infarction (AMI), whereas older women in similar
circumstances often present with larger number of comorbidities that adversely influence
the outcome, when compared to men (Coronado et al 1997). Women with acute coronary
syndromes (ACS) are also less likely to receive rapid effective diagnosis and treatment
than are men (Ayanian and Epstein 1991; Maynard et al 1996; Pope
et al 2000).
Regarding the North American population, the Women’s Ischemic Syndrome
Evaluation (WISE) study workshop (Hayes et al 2004; Maseri 2004; Nabel et al 2004;
Pepine et al 2004; Shaw et al 2004; Waters et al 2004) from the National Heart, Lung and
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far (Table 1), all of these trials enrolled patients with LDL 
cholesterols above 3.0 mmol/L. Further, while subgroup 
analyses demonstrated similar beneﬁ  ts across baseline LDL 
cholesterol levels, it should be recognized that even the low-
est tertile in these analyses incorporated patients with baseline 
LDL cholesterols as high as 3.5 mmol/L. Thus, the question 
of “how low should we go in lowering LDL cholesterol” 
remained unanswered even after these 17 placebo-controlled 
statin trials were completed.
In an attempt to address the issue of optimal LDL choles-
terol target levels, recent statin trials have compared higher 
dose statin therapy to the lower dose statin therapy employed 
in the 17 placebo-controlled trials which established the efﬁ  -
cacy of statins for preventing cardiovascular events (outlined 
in Table 1). It deserves emphasis that since these trials com-
pared different ﬁ  xed doses of statins with each other rather 
than titrating drug doses to achieve different target LDL 
levels, they cannot provide an unconfounded answer to the 
target LDL question. While this may seem like an argument 
over semantics, it is not. As pointed out by others, “compared 
with empirically treating patients…with statin doses similar 
to those used in clinical trials, titrating lipid therapy to recom-
mended LDL cholesterol goals entails considerably greater 
clinical complexity, frequent use of multidrug therapy, and 
greater…costs” (Hayward et al 2006, page 521). Given the 
paucity of published evidence exploring the beneﬁ  ts of dif-
ferent LDL cholesterol targets in unconfounded analyses, our 
review will instead explore the question that can be answered 
from the existing trial literature – what statin dose should we 
use in patients with coronary heart disease? In order to answer 
this question, in this review we will examine the evidence 
from randomized trials comparing higher dose statin therapy 
versus lower dose statin therapy.
The randomized trials of higher dose 
statins versus lower dose statins
Trials reporting surrogate endpoints
The ASAP trial
The Effect of Aggressive versus conventional lipid 
lowering in Atherosclerosis Progression in familial 
hypercholesterolemia trial randomized 325 patients 
with familial hypercholesterolemia to atorvastatin 80 
mg daily or simvastatin 40 mg daily (Smilde et al 2001). 
The primary endpoint was change in atheroma volume 
as assessed by quantitative B-mode ultrasound of carotid 
intima media thickness (IMT). LDL cholesterol lowering 
was significantly greater (p = 0.0001) with atorvastatin 
(from 8.00 mmol/L to 3.88 mmol/L) than simvastatin 
(from 8.33 mmol/L to 4.81 mmol/L). After 2 years, IMT 
decreased in the patients randomized to atorvastatin 
therapy (–0.031 mm, 95% CI –0.007 to −0.055) but 
increased in the simvastatin-treated patients (+0.036 mm, 
95% CI + 0.014 to + 0.058) – this between-group differ-
ence was highly statistically significant (p = 0.0001). Both 
treatment regimens were equally well tolerated. 
The ARBITER trial
The Arterial Biology for the Investigation of the Treat-
ment Effects of Reducing cholesterol trial randomized 
161 patients meeting National Cholesterol Education 
Program II criteria for lipid-lowering therapy (46% of 
whom had known cardiovascular disease) to atorvastatin 
80 mg daily or pravastatin 40 mg daily (Taylor et al 2002). 
The primary endpoint was change in carotid IMT. LDL 
cholesterol lowering was significantly greater (p   0.001) 
with atorvastatin (from 3.80 mmol/L to 1.95 mmol/L) 
than pravastatin (from 3.98 mmol/L to 2.82 mmol/L) 
at 12 months. After 12 months, IMT decreased in the 
patients randomized to atorvastatin therapy (–0.034 mm 
± 0.021 mm) but did not appreciably change in the sim-
vastatin-treated patients (+0.025 mm ± 0.017 mm) – this 
between-group difference was statistically significant 
(p = 0.03). No patient in either treatment arm suffered a 
drug-related side effect. 
Trials reporting clinical endpoints
The Post-CABG trial 
The Post Coronary Artery Bypass Graft Trial randomized 
1351 patients who had undergone bypass surgery in the 
preceding decade, still had at least one patent vein graft 
on angiography, and who had an LDL cholesterol level 
between 3.34 mmol/L and 4.49 mmol/L to aggressive or 
moderate intensity treatment to lower LDL cholesterol 
levels (with lovastatin and, if needed, cholestyramine) 
and, using a two-by-two factorial design, to treatment with 
warfarin or placebo (The Post Coronary Artery Bypass 
Graft Trial Investigators 1997). The primary endpoint 
was the per-patient percentage of initially patent major 
grafts that had substantial progression of atherosclerosis (a 
decrease of 0.6 mm or more in lumen diameter) at the site 
of greatest change at follow-up. During follow-up, patients 
assigned to the aggressive lipid treatment group were tak-
ing a mean of 76 mg lovastatin daily (30% were also taking 
8 g of cholestyramine daily) and patients assigned to the 
moderate lipid treatment group were taking a mean of 4 Vascular Health and Risk Management 2006:2(4) 465–475
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Introduction
The first female-specific recommendations for preventive cardiology were published in
1999 (Mosca et al 1999). Even though research in the treatment of cardiovascular disease
(CVD) had advanced in many areas, it remains the leading cause of death in women in
most parts of the world. Studies have shown that 500 thousand women die of CVD every
year in the United States, somewhat near one death every minute (American Heart
Association 2003). Such index exceeds not only the number of deaths in men, but also the
next seven causes of death in women combined, and more importantly, coronary artery
disease (CAD) is believed to be the major cause responsible for these deaths (American
Heart Association 2003). Over a quarter of a million deaths per year are attributed to CAD
alone in the United States (Merz et al 2004). Although already high, these figures are
expected to rise even more during the next decades, due to an increase of diabetes and
obesity, as well as the aging of the world population (Merz et al 2004).
Even though women have a higher frequency of chest pain/angina than men, the
incidence of obstructive CAD in the female population is lower when compared with
men with similar symptoms (Kenedy et al 1982; Diamond et al 1983; Merz et al 1999). In
addition, it would appear that young women with obstructive CAD have a worse
prognosis after acute myocardial infarction (AMI), whereas older women in similar
circumstances often present with larger number of comorbidities that adversely influence
the outcome, when compared to men (Coronado et al 1997). Women with acute coronary
syndromes (ACS) are also less likely to receive rapid effective diagnosis and treatment
than are men (Ayanian and Epstein 1991; Maynard et al 1996; Pope
et al 2000).
Regarding the North American population, the Women’s Ischemic Syndrome
Evaluation (WISE) study workshop (Hayes et al 2004; Maseri 2004; Nabel et al 2004;
Pepine et al 2004; Shaw et al 2004; Waters et al 2004) from the National Heart, Lung and
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Table 1 Placebo-controlled statin trials which randomized greater than 250 participants
Trial  Study  Treatment dose  Key eligibility criteria  Control  Treatment  LDL subgroup
  design      group LDL  group LDL at  analysis
       at  baseline/  baseline/at
       at  follow-up  follow-up
4S  Secondary   Simvastatin   35–70 yrs, prior   4.87/4.92  4.87/3.17  None
  prevention,   20–40 mg  angina or AMI,      
  multicenter,    fasting total chol      
  median f/u     5.5–8.0 mmol/L     
 5.4  years         
WOSCOPS  Primary   Pravastatin   45–64 yrs, no prior   4.97/not   4.97/3.68  Baseline LDL   4.9
  prevention,   40 mg  AMI, fasting LDL chol  reported     vs   4.9
  one center,     4.0–6.0 mmol/L
 mean  f/u
 4.9  years
CARE  Secondary   Pravastatin   21–75 yrs, prior AMI,   3.6/  3.6/2.5  Baseline LDL  3.2 
  prevention,  40 mg  fasting LDL chol       vs 3.2–3.9 vs 3.91–4.5
 multicenter    3.0–4.5  mmol/L     
AFCAPS/   Primary   Lovastatin   45–73 yrs (males) or   3.89/4.04   3.89/2.96  None
TexCAPS  prevention,   20–40 mg  55–73 (females), no   (at 1 year)   
  multicenter,    prior AMI, fasting LDL     
  mean f/u      chol 3.4–4.9 mmol/L     
 5.2  years         
LIPID  Secondary  Pravastatin  31–75 yrs,  3.9/not  3.9/reduced   Baseline LDL   
  prevention,   40 mg  prior AMI or unstable  reported  by 25% more  3.5 vs 3.5–4.5 vs 
  multicenter,    angina, fasting total     than placebo    4.5
  mean f/u     chol 4–7 mmol/L    group
 6.1  years
GISSI  Secondary  Pravastatin   Recent MI ( 6   3.9/3.8  3.9/3.3  Baseline LDL   
prevention  prevention,  20 mg  months), total       3.4 vs   3.4
 multicenter,    cholestrol    5.18
  mean f/u 23    mmol/L
 months
HPS  Primary and  Simvastatin   40–80 yrs, with   3.4/not   3.4/(1.0   Baseline LDL   
  secondary   40 mg  coronary disease,   reported  mmol/L less   3.0 vs 3.1–3.4 
  prevention,     other occlusive     than placebo)  vs   3.5
  multicenter,    arterial disease, or      
  mean f/u 5     diabetes, with non-     
  years    fasting tot chol of  3.5    
          
MIRACL Secondary  Atorvastatin  18 yrs, unstable  3.2/3.5 (at   3.2/1.9 (at 16  Baseline LDL 
  prevention,  80 mg  angina or non-Q-  16 weeks)  weeks)    3.1 vs   3.1
 multicenter,    wave  AMI
  16 weeks f/u
Serruys   Secondary   Fluvastatin   18–80 yrs, pts with   3.4/3.8 (at   3.4/2.5 (at 6   Baseline LDL   3.4 
study   prevention,   80 mg  stable or unstable   6 weeks)  weeks)  vs   3.4
(LIPS)  multicenter,    angina or silent      
  median f/u     ischemia who      
  3.9 years    underwent PCI, tot
      chol 3.5–7.0 mmol/L     
PROSPER  Primary and  Pravastatin   70–82 yrs, with   3.8/  3.8/2.8  Baseline LDL   3.41
  secondary   40 mg  history of or risk       vs 3.41–4.11 vs  
  prevention,    factors for vascular      4.11
 multicenter,    disease     
   mean f/u
 3.2  years
ASCOTT-  Primary   Atorvastatin   40–79 yrs,   3.44/3.45   3.44/2.21  None
LLA  prevention,  10 mg  hypertensive pts with  (at 6
  multicenter,    at least 3 additional    months;    
  median f/u    CHD risk factors,  1,2,3 yr 
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Introduction
The first female-specific recommendations for preventive cardiology were published in
1999 (Mosca et al 1999). Even though research in the treatment of cardiovascular disease
(CVD) had advanced in many areas, it remains the leading cause of death in women in
most parts of the world. Studies have shown that 500 thousand women die of CVD every
year in the United States, somewhat near one death every minute (American Heart
Association 2003). Such index exceeds not only the number of deaths in men, but also the
next seven causes of death in women combined, and more importantly, coronary artery
disease (CAD) is believed to be the major cause responsible for these deaths (American
Heart Association 2003). Over a quarter of a million deaths per year are attributed to CAD
alone in the United States (Merz et al 2004). Although already high, these figures are
expected to rise even more during the next decades, due to an increase of diabetes and
obesity, as well as the aging of the world population (Merz et al 2004).
Even though women have a higher frequency of chest pain/angina than men, the
incidence of obstructive CAD in the female population is lower when compared with
men with similar symptoms (Kenedy et al 1982; Diamond et al 1983; Merz et al 1999). In
addition, it would appear that young women with obstructive CAD have a worse
prognosis after acute myocardial infarction (AMI), whereas older women in similar
circumstances often present with larger number of comorbidities that adversely influence
the outcome, when compared to men (Coronado et al 1997). Women with acute coronary
syndromes (ACS) are also less likely to receive rapid effective diagnosis and treatment
than are men (Ayanian and Epstein 1991; Maynard et al 1996; Pope
et al 2000).
Regarding the North American population, the Women’s Ischemic Syndrome
Evaluation (WISE) study workshop (Hayes et al 2004; Maseri 2004; Nabel et al 2004;
Pepine et al 2004; Shaw et al 2004; Waters et al 2004) from the National Heart, Lung and
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mg of lovastatin daily (and only 5% were also taking 8 g 
of cholestyramine daily). LDL cholesterol was reduced to 
2.4 mmol/L in the aggressive treatment group and 3.5 mmol/L 
in the moderate treatment arm. After a mean follow-up of 
4.3 years, the number of grafts demonstrating substantial 
progression of disease was statistically signiﬁ  cantly reduced 
in the aggressive-treatment group (27% vs. 39%, p   0.001). 
No signiﬁ  cant differences in angiographic outcomes were 
observed between the warfarin and placebo groups and there 
was no interaction between warfarin and aggressive lipid 
lowering. Clinical events and adverse effects were uncom-
mon and did not differ signiﬁ  cantly between groups.
Table 1 (Continued)
Trial  Study  Treatment dose  Key eligibility criteria  Control  Treatment  LDL subgroup
  design      group LDL  group LDL at  analysis
       at  baseline/  baseline/at
       at  follow-up  follow-up
  3.3 years    non-fasting total chol  data avail)
      6.5 mmol/L
ALLHAT-  Primary and  Pravastatin    55yrs with stage 1   3.8/3.3 ( at   3.8/2.7  Baseline LDL   
LLT  secondary   40 mg   or 2 hypertension &   4 years;     3.37 vs.   3.37
  prevention,     one additional CHD   data for yr    
  multicenter,    risk, fasting LDL 3.1–  2 & 6 also    
  mean f/u     4.9 mmol/L for no   avail)   
  4.8 years    known CHD vs..     
      2.6–3.3 mmol/L for     
     known  CHD    
ALERT  Primary and  Fluvastatin   30–75 yrs, prev renal   4.1/  4.1/2.8 (at   None
  secondary  40 mg  or combined renal    end of study)
  prevention,     and pancreas      
  multicenter,    transplants, tot chol      
  mean f/u    4.0–9.0 mmol/L in pts     
  5.1 years    with no CHD vs. 4.0–     
      7.0 mmol/L for known     
     CHD     
CARDS  Primary   Atorvastatin   40–75 yrs, with type 2  3.02/3.07   3.04/1.75  -Baseline LDL   
  prevention,   10 mg  diabetes and at least  (at 6     3.1, 39/696 
  multicenter,    one of: retinopathy,   months;     atorvastatin vs. 
  median f/u     albuminuria, current   values at     61/718 placebo, 
  3.9 years    smoking, or   1,2, and 4     HR 0.63
     hypertension;  LDL      years also     -Baseline LDL
     4.14  mmol/L avail)      3.1, 44/721 
           atorvastatin  vs. 
            66/695 placebo, HR
           0.62
SPARCL  Secondary   Atorvastatin    18 yrs, prior   3.46/3.32  3.44/1.89  None
  prevention,   80 mg  ischemic or      
  multicenter,    hemorrhagic stroke      
  median f/u     or TIA, LDL chol 2.6–     
  4.9 years    4.9 mmol/L     
FLORIDA Secondary    Fluvastatin   18 yrs, AMI, total   3.6/3.9  3.5/2.7  None
  prevention,   80 mg  chol   6.5 mmol/L     
 multicenter,         
  median f/u          
 1  year         
AVERT  Secondary   Atorvastatin 80  Stable CAD, stenosis  3.8/3.1  3.7/2.0  None
  prevention,    mg vs. PCI   of  50% in at least      
  multicenter,    one coronary artery,      
  f/u 18     LDL  3.0 mmol/L,      
 months    triglycerides    5.6      
     mmol/L     Vascular Health and Risk Management 2006:2(4) 465–475
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Abstract: Despite numerous studies on women’s cardiac health throughout the past decade, the
number of female deaths caused by cardiovascular disease still rises and remains the leading cause
of death in women in most areas of the world. Novel studies have demonstrated that cardiovascular
disease, and more specifically coronary artery disease presentations in women, are different than
those in men. In addition, pathology and pathophysiology of the disease present significant
gender differences, which leads to difficulties concerning diagnosis, treatment and outcome of the
female population. The reason for this disparity is all steps for female cardiovascular disease
evaluation, treatment and prevention are not well elucidated; and an area for future research. This
review brings together the most recent studies published in the field of coronary artery disease
in women and points out new directions for future investigation on some of the important issues.
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Introduction
The first female-specific recommendations for preventive cardiology were published in
1999 (Mosca et al 1999). Even though research in the treatment of cardiovascular disease
(CVD) had advanced in many areas, it remains the leading cause of death in women in
most parts of the world. Studies have shown that 500 thousand women die of CVD every
year in the United States, somewhat near one death every minute (American Heart
Association 2003). Such index exceeds not only the number of deaths in men, but also the
next seven causes of death in women combined, and more importantly, coronary artery
disease (CAD) is believed to be the major cause responsible for these deaths (American
Heart Association 2003). Over a quarter of a million deaths per year are attributed to CAD
alone in the United States (Merz et al 2004). Although already high, these figures are
expected to rise even more during the next decades, due to an increase of diabetes and
obesity, as well as the aging of the world population (Merz et al 2004).
Even though women have a higher frequency of chest pain/angina than men, the
incidence of obstructive CAD in the female population is lower when compared with
men with similar symptoms (Kenedy et al 1982; Diamond et al 1983; Merz et al 1999). In
addition, it would appear that young women with obstructive CAD have a worse
prognosis after acute myocardial infarction (AMI), whereas older women in similar
circumstances often present with larger number of comorbidities that adversely influence
the outcome, when compared to men (Coronado et al 1997). Women with acute coronary
syndromes (ACS) are also less likely to receive rapid effective diagnosis and treatment
than are men (Ayanian and Epstein 1991; Maynard et al 1996; Pope
et al 2000).
Regarding the North American population, the Women’s Ischemic Syndrome
Evaluation (WISE) study workshop (Hayes et al 2004; Maseri 2004; Nabel et al 2004;
Pepine et al 2004; Shaw et al 2004; Waters et al 2004) from the National Heart, Lung and
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Aggressive statin therapy
The REVERSAL trial
The REVERSal of atherosclerosis with Aggressive Lipid 
lowering Trial randomized 654 patients with angio-
graphically proven CAD to atorvastatin 80 mg daily or 
pravastatin 40 mg daily (Nissen et al 2004). The primary 
endpoint was change in atheroma volume assessed by 
intravascular ultrasound. LDL cholesterol lowering was 
significantly greater (p   0.001) with atorvastatin (from 
3.86 mmol/L to 2.03 mmol/L) than pravastatin (from 
3.86 mmol/L to 2.84 mmol/L) at the end of the 18 month 
follow-up in this trial. After 18 months, atheroma volume 
progressed in the pravastatin arm (+2.7%, 95% CI 
0.24% to 4.67%) but was stable in the patients random-
ized to atorvastatin therapy (–0.4%, 95% CI –2.35% to 
+1.49%) – this between-group difference was statistically 
signiﬁ  cant (p = 0.02). The beneﬁ  cial effects of atorvastatin 
on atheroma progression were seen in all 23 subgroups 
examined. Both treatment regimens were equally well tol-
erated, although there were too few cardiovascular events 
(15) or drug-related discontinuations/adverse effects 
(43) for useful comparisons between treatment arms.
The PROVE IT- TIMI 22 trial
The Pravastatin or Atorvastatin Evaluation and Infection 
Therapy – Thrombolysis in Myocardial Infarction 22 Trial 
randomized 4,162 patients with acute coronary syndrome to 
either atorvastatin 80 mg daily or pravastatin 40 mg daily 
(Cannon et al 2004). The primary endpoint was a composite 
of death from any cause, myocardial infarction, unstable 
angina requiring hospitalization, revascularization (per-
formed at least 30 days after randomization), or stroke. LDL 
cholesterol lowering was signiﬁ  cantly greater (p   0.001) 
with atorvastatin (from 2.74 mmol/L to 1.60 mmol/L) than 
pravastatin (from 2.74 mmol/L to 2.46 mmol/L) at the end 
of the trial (24 months). At the end of 24 months, the rates of 
the primary endpoint were 22.4% in the atorvastatin group 
and 26.3% in the pravastatin group – this between-group 
difference was statistically signiﬁ  cant (p = 0.005). The 
beneﬁ  cial effects of atorvastatin on the primary endpoint 
were consistent across all 17 subgroups examined, with 
the beneﬁ  ts appearing to be greater in those patients with 
baseline LDL cholesterol levels of at least 3.2 mmol/L 
(p = 0.02 for interaction). The intensive treatment arm had 
a statistically signiﬁ  cant increase in rates of alanine ami-
notransferase elevations when compared to the moderate 
lipid lowering treatment arm (p   0.001), but there were no 
signiﬁ  cant differences between groups in myopathy or drug 
discontinuation rates.
Phase Z of the A to Z trial
Phase Z of the A to Z Trial randomized 4,497 patients 
with acute coronary syndrome (ACS) to receive 40 mg 
of simvastatin daily for 1 month followed by 80 mg daily 
thereafter or placebo for 4 months followed by 20 mg of sim-
vastatin daily (de Lemos et al 2004). The primary endpoint 
was a composite of cardiovascular death, nonfatal myocardial 
infarction, readmission for ACS, or stroke. LDL cholesterol 
lowering was signiﬁ  cantly greater (p   0.001) with the higher 
dose simvastatin group (from 2.90 mmol/L to 1.71 mmol/L) 
than the lower dose simvastatin group (from 2.87 mmol/L 
to 2.10 mmol/L) at the end of the trial (24 months). After 
24 months, the primary endpoint occurred in 14.4% of the 
higher dose simvastatin group and 16.7% in the lower dose 
group – this between-group difference was not statistically 
signiﬁ  cant (p = 0.14 ). There were no signiﬁ  cant treatment 
interactions in any of the 21 subgroups examined. The higher 
dose treatment arm demonstrated statistically signiﬁ  cant 
increases in liver enzyme elevations and myopathy when 
compared to the lower dose treatment arm. 
The Vascular Basis for the Treatment of Myocardial 
Ischemia Study
The Vascular Basis for the Treatment of Myocardial Ischemia 
Study randomized 300 patients with stable CAD and a posi-
tive exercise stress test to one of 3 groups: atorvastatin 80 mg 
daily, atorvastatin 80 mg daily plus vitamins C and E, or the 
control group of low dose (median 5 mg) lovastatin (Stone 
et al 2005). The primary endpoint was number of ischemic 
episodes on ambulatory ECG monitoring. LDL cholesterol 
lowering was signiﬁ  cantly greater (p   0.0001) in both of 
the atorvastatin groups (from 3.9 mmol/L to 2.2 mmol/L) 
than in the lovastatin (from 3.9 mmol/L to 3.2 mmol/L) at 
the end of the trial (12 months). After 12 months, patients 
in all 3 treatment arms experienced signiﬁ  cant declines 
in the frequency and duration of myocardial ischemia 
episodes – between 31% and 61%, but with no statistically 
signiﬁ  cant difference between groups (p = 0.15). There were 
too few clinical events (12 deaths, MI, unstable angina, or 
stroke) to draw conclusions between treatment arms and no 
adverse events were reported.
The TNT trial
The Treating to New Targets Trial randomized 10,001 
patients with stable CAD to either atorvastatin 80 mg daily 
or atorvastatin 10 mg daily after completion of an open-label 
run-in period (LaRosa et al 2005). The primary endpoint 
was the occurrence of a ﬁ  rst major cardiovascular event, Vascular Health and Risk Management 2006:2(4) 465–475
© 2006 Dove Medical Press Limited. All rights reserved
465
REVIEW
Leila Fernandes Araujo
Alexandre de Matos Soeiro
Juliano Lara Fernandes
Antônio Eduardo Pesaro
Carlos V Serrano Jr
Heart Institute (InCor), University
of São Paulo, School of Medicine,
Brazil
Correspondence: Carlos V Serrano Jr
Coronary Care Unit, Av. Dr. Enéas
Carvalho Aguiar, 44 – sala 12 – bloco 2,
São Paulo - SP - 05403-900, Brazil
Tel +55 11 3069 5058
Fax +55 11 3088 3809
Email carlos.serrano@incor.usp.br
Abstract: Despite numerous studies on women’s cardiac health throughout the past decade, the
number of female deaths caused by cardiovascular disease still rises and remains the leading cause
of death in women in most areas of the world. Novel studies have demonstrated that cardiovascular
disease, and more specifically coronary artery disease presentations in women, are different than
those in men. In addition, pathology and pathophysiology of the disease present significant
gender differences, which leads to difficulties concerning diagnosis, treatment and outcome of the
female population. The reason for this disparity is all steps for female cardiovascular disease
evaluation, treatment and prevention are not well elucidated; and an area for future research. This
review brings together the most recent studies published in the field of coronary artery disease
in women and points out new directions for future investigation on some of the important issues.
Keywords: coronary artery disease, women, risk factors, prevention, diagnosis, treatment.
Introduction
The first female-specific recommendations for preventive cardiology were published in
1999 (Mosca et al 1999). Even though research in the treatment of cardiovascular disease
(CVD) had advanced in many areas, it remains the leading cause of death in women in
most parts of the world. Studies have shown that 500 thousand women die of CVD every
year in the United States, somewhat near one death every minute (American Heart
Association 2003). Such index exceeds not only the number of deaths in men, but also the
next seven causes of death in women combined, and more importantly, coronary artery
disease (CAD) is believed to be the major cause responsible for these deaths (American
Heart Association 2003). Over a quarter of a million deaths per year are attributed to CAD
alone in the United States (Merz et al 2004). Although already high, these figures are
expected to rise even more during the next decades, due to an increase of diabetes and
obesity, as well as the aging of the world population (Merz et al 2004).
Even though women have a higher frequency of chest pain/angina than men, the
incidence of obstructive CAD in the female population is lower when compared with
men with similar symptoms (Kenedy et al 1982; Diamond et al 1983; Merz et al 1999). In
addition, it would appear that young women with obstructive CAD have a worse
prognosis after acute myocardial infarction (AMI), whereas older women in similar
circumstances often present with larger number of comorbidities that adversely influence
the outcome, when compared to men (Coronado et al 1997). Women with acute coronary
syndromes (ACS) are also less likely to receive rapid effective diagnosis and treatment
than are men (Ayanian and Epstein 1991; Maynard et al 1996; Pope
et al 2000).
Regarding the North American population, the Women’s Ischemic Syndrome
Evaluation (WISE) study workshop (Hayes et al 2004; Maseri 2004; Nabel et al 2004;
Pepine et al 2004; Shaw et al 2004; Waters et al 2004) from the National Heart, Lung and
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defined as death from coronary heart disease, nonfatal 
non-procedure-related myocardial infarction, resuscitation 
after cardiac arrest, or fatal/nonfatal stroke. LDL cholesterol 
lowering was signiﬁ  cantly greater (p   0.001) with high 
dose atorvastatin (from 2.6 mmol/L to 2.0 mmol/L) than 
low dose atorvastatin (remained unchanged from post run-
in period value of 2.6 mmol/L) at the end of the trial (4.9 
years). After 4.9 years, 8.7% of patients in the higher dose 
group had a primary event vs 10.9% in the lower dose group 
– this between-group difference was statistically signiﬁ  cant 
(p   0.001). When compared to patients receiving 10 mg 
of atorvastatin, those receiving 80 mg of atorvastatin dem-
onstrated statistically signiﬁ  cant increases in liver enzyme 
elevations as well as increased rates of drug discontinuation 
due to adverse events (p   0.001 for both). 
The IDEAL trial
The Incremental Decrease in End points through Aggressive 
Lipid lowering Trial randomized 8,888 with stable CAD to 
atorvastatin 80 mg daily or simvastatin 20 mg daily (Pedersen 
et al 2005). The primary endpoint was time to ﬁ  rst occur-
rence of a major coronary event, deﬁ  ned as coronary death, 
hospitalization for nonfatal acute myocardial infarction, or 
cardiac arrest with resuscitation. LDL cholesterol lower-
ing was signiﬁ  cantly greater (p   0.001) with atorvastatin 
(from 3.15 mmol/L to 2.07 mmol/L) than simvastatin (from 
3.14 mmol/L to 2.58 mmol/L). After 4.8 years, 9.3% of the 
atorvastatin group had suffered a primary outcome vs 10.4% 
of the simvastatin group – this between-group difference was 
not statistically signiﬁ  cant (p = 0.07). Patients in the high 
dose treatment arm had a statistically signiﬁ  cant increases in 
liver enzyme elevations and adverse events leading to drug 
discontinuation when compared to those in the lower dose 
treatment arm (both p   0.001).
Summary of the higher dose vs 
lower dose statin trials
These 9 trials report data from 29,853 patients with coronary 
artery disease and 486 patients with other indications for 
statin therapy randomized to higher dose vs. lower dose 
statin therapy. Study participants in the 7 trials of secondary 
prevention were demographically similar, although baseline 
LDL cholesterols ranged between 2.74 mmol/L in PROVE 
IT to 3.98 mmol/L in Post-CABG (Table 2). These trials 
were methodologically robust (all scored greater than 3 
on the 5-point Jadad scale for randomized trials) but some 
potential threats to the generalizability of study results are 
worth pointing out. For example, the TNT trial excluded 
almost half of those initially screened and included a run-in 
phase before randomization (both design features can bias 
the results towards an underestimation of adverse effects 
and an overestimation of beneﬁ  ts since patients who are 
identiﬁ  ed to be at increased risk for adverse effects due 
to comorbidities at screening, or indeed suffer adverse 
effects during the run-in phase, are excluded). Further, the 
proportion of patients using statins prior to randomiza-
tion varied widely amongst the trials, with only A-to-Z 
excluding anyone previously using statins (inclusion of 
patients previously exposed to a medication can also bias 
results towards an underestimation of adverse effects and 
an overestimation of beneﬁ  ts).
Pooled results from the seven higher 
dose vs lower dose statin trials in 
patients with coronary disease
Changes in LDL cholesterol and reductions in 
primary endpoints (Figure 1)
Patients treated with higher dose statins in all trials achieved 
lower LDL cholesterols than those treated with lower dose 
statins (Figure 1) and higher dose statins were associated 
with relative reductions in each study’s primary endpoint 
compared to lower intensity statin treatment (from 11% in 
IDEAL to 20% in TNT). The differences in achieved LDL 
levels between the higher and lower dose statin arms ranged 
from a low of 0.39 mmol/L in the A-to-Z Trial to 1.0 mmol/L 
in the Vascular Basis Trial.
All-cause mortality (Figure 2)
Higher dose statin therapy was associated with non-
signiﬁ  cant trends towards lower all-cause mortality rates 
in 4 of the 7 secondary prevention trials (with OR ranging 
from 0.71 (95% CI 0.49–1.02) in PROVE-IT TIMI 22 to 
0.98 (95% CI 0.84–1.14) in IDEAL) – pooling the data 
across all 7 trials using a random effects model revealed 
a 25% reduction in mortality in patients after acute coro-
nary syndromes (OR 0.75; 95% CI 0.61–0.93) with higher 
dose statin therapy, but no apparent impact on mortality in 
patients with chronic CAD (OR 0.99; 95% CI 0.89–1.10) 
(Josan et al 2007).
Myocardial infarction or coronary death (Figure 2)
Higher dose statins were associated with a significant 
reduction in this composite endpoint in the TNT trial (OR 
0.79, 95% CI 0.68–0.91) and non-signiﬁ  cant trends towards 
lower event rates in 5 of the other 6 trials (with OR rang-
ing from 0.57 (95% CI 0.16–1.95) in REVERSAL to 0.88 Vascular Health and Risk Management 2006:2(4) 465–475
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Introduction
The first female-specific recommendations for preventive cardiology were published in
1999 (Mosca et al 1999). Even though research in the treatment of cardiovascular disease
(CVD) had advanced in many areas, it remains the leading cause of death in women in
most parts of the world. Studies have shown that 500 thousand women die of CVD every
year in the United States, somewhat near one death every minute (American Heart
Association 2003). Such index exceeds not only the number of deaths in men, but also the
next seven causes of death in women combined, and more importantly, coronary artery
disease (CAD) is believed to be the major cause responsible for these deaths (American
Heart Association 2003). Over a quarter of a million deaths per year are attributed to CAD
alone in the United States (Merz et al 2004). Although already high, these figures are
expected to rise even more during the next decades, due to an increase of diabetes and
obesity, as well as the aging of the world population (Merz et al 2004).
Even though women have a higher frequency of chest pain/angina than men, the
incidence of obstructive CAD in the female population is lower when compared with
men with similar symptoms (Kenedy et al 1982; Diamond et al 1983; Merz et al 1999). In
addition, it would appear that young women with obstructive CAD have a worse
prognosis after acute myocardial infarction (AMI), whereas older women in similar
circumstances often present with larger number of comorbidities that adversely influence
the outcome, when compared to men (Coronado et al 1997). Women with acute coronary
syndromes (ACS) are also less likely to receive rapid effective diagnosis and treatment
than are men (Ayanian and Epstein 1991; Maynard et al 1996; Pope
et al 2000).
Regarding the North American population, the Women’s Ischemic Syndrome
Evaluation (WISE) study workshop (Hayes et al 2004; Maseri 2004; Nabel et al 2004;
Pepine et al 2004; Shaw et al 2004; Waters et al 2004) from the National Heart, Lung and
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Aggressive statin therapy
(95% CI 0.71–1.01) in IDEAL). Pooling the data across all 
7 trials using a random effects model conﬁ  rmed that higher 
dose statins provided further reductions (over lower dose 
statin therapy) in myocardial infarction or coronary death 
in patients after acute coronary syndromes (OR 0.84; 95% 
CI 0.72–0.97) and in patients with chronic CAD (OR 0.84; 
95% CI 0.76–0.92) (Josan et al 2007).
Stroke (Figure 2)
Higher dose statins signiﬁ  cantly reduced stroke in the TNT 
trial (OR 0.75, 95% CI 0.59–0.96) and was associated with 
trends to beneﬁ  t in 3 of the other 6 trials. Pooling the data 
across all 7 trials using a random effects model conﬁ  rmed 
that, compared to lower dose statin therapy, higher dose 
statins further reduced stroke in patients with chronic CAD 
(OR 0.82; 95% CI 0.70–0.96); although a similar trend was 
observed in patients after acute coronary syndromes (OR 
0.91; 95% CI 0.61–1.35) there were too few events in this 
smaller subgroup of patients for the data to be deﬁ  nitive 
(Josan et al 2007).
Non-cardiovascular mortality (Figure 2)
There was no appreciable difference between higher or lower 
dose statin therapy in any of the trials or either in patients 
with chronic CAD (OR 1.07, 95% CI 0.79–1.46) or in patients 
after acute coronary syndromes (OR 0.78, 95% CI 0.49–1.24) 
when the data were pooled across trials.
Adverse events
Discontinuation of study drug due to adverse events was 
higher in the higher dose statin arms of these trials (pooled 
estimate 7.7% versus 5.1% for the lower dose statin arms, 
Table 2 Randomized trials comparing higher dose statin therapy with lower dose statin therapy in patients with coronary artery disease
Trial  Sample  Comparators  Key eligibility   Key   LDL at follow-  LDL at follow-  Duration of 
  size    criteria  demographics   up (more   up (less   follow-up
        (mean age,   intensive   intensive  
        % men, mean   therapy arm)  therapy arm) 
       LDL  at  baseline)    
Post-CABG  1351  Lovastatin 80 mg  Post CABG 1–11   62 years  2.4 mmol/L  3.5 mmol/L  4.3 years
    vs lovastatin   years before  92%     
    5 mg    3.98 mmol/L     
REVERSAL  654  Pravastatin 40 mg  Stable CAD  56 years  2.04 mmol/L  2.85 mmol/L  18 months
    vs atorvastatin     72%     
    80 mg    3.9 mmol/L     
Vascular basis  300  Lovastatin 5 mg  Stable  CAD  not reported  2.2 mmol/L  3.2 mmol/L  12 months
    vs atorvastatin     86%     
    80 mg vs    3.9 mmol/L     
    atorvastatin 80          
    mg + antioxidant         
PROVE   4,162  Pravastatin 40 mg  Post ACS  58 years  1.60 mmol/L  2.46 mmol/L  24 months
IT-TIMI 22    vs atorvastatin     78%      
    80 mg    2.74 mmol/L     
A to Z  4,497  Placebo ×   Post ACS  61 years  1.71 mmol/L  2.10 mmol/L  24 months
    4 months then     76%     
    simvastatin     2.89 mmol/L     
    20 mg vs          
   simvastatin           
   40  mg  × 1 month         
    then 80 mg         
TNT  10,001  Atorvastatin   Stable CAD  61 years  2.0 mmol/L  2.6 mmol/L  4.9 years
    10 mg vs 80 mg    81%     
        2.6 mmol/L (after     
       run-in)     
IDEAL 8,888  Simvastatin   Stable CAD  62 years  2.1 mmol/L  2.7 mmol/L  4.8 years
    20 mg vs     81%   
    atorvastatin     3.2 mmol/L    
   80  mgVascular Health and Risk Management 2006:2(4) 465–475
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The first female-specific recommendations for preventive cardiology were published in
1999 (Mosca et al 1999). Even though research in the treatment of cardiovascular disease
(CVD) had advanced in many areas, it remains the leading cause of death in women in
most parts of the world. Studies have shown that 500 thousand women die of CVD every
year in the United States, somewhat near one death every minute (American Heart
Association 2003). Such index exceeds not only the number of deaths in men, but also the
next seven causes of death in women combined, and more importantly, coronary artery
disease (CAD) is believed to be the major cause responsible for these deaths (American
Heart Association 2003). Over a quarter of a million deaths per year are attributed to CAD
alone in the United States (Merz et al 2004). Although already high, these figures are
expected to rise even more during the next decades, due to an increase of diabetes and
obesity, as well as the aging of the world population (Merz et al 2004).
Even though women have a higher frequency of chest pain/angina than men, the
incidence of obstructive CAD in the female population is lower when compared with
men with similar symptoms (Kenedy et al 1982; Diamond et al 1983; Merz et al 1999). In
addition, it would appear that young women with obstructive CAD have a worse
prognosis after acute myocardial infarction (AMI), whereas older women in similar
circumstances often present with larger number of comorbidities that adversely influence
the outcome, when compared to men (Coronado et al 1997). Women with acute coronary
syndromes (ACS) are also less likely to receive rapid effective diagnosis and treatment
than are men (Ayanian and Epstein 1991; Maynard et al 1996; Pope
et al 2000).
Regarding the North American population, the Women’s Ischemic Syndrome
Evaluation (WISE) study workshop (Hayes et al 2004; Maseri 2004; Nabel et al 2004;
Pepine et al 2004; Shaw et al 2004; Waters et al 2004) from the National Heart, Lung and
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p   0.0001) (Josan et al 2007). In contrast, the discontinu-
ation rate attributed to study drug in the placebo-controlled 
trials in Table 1 was 7.7% in 25,723 placebo-treated patients 
and 7.8% in 25,742 statin-treated patients (p = 0.98). The 
frequency of elevated transaminases (AST or ALT greater 
than 3 times the upper limit of normal) was signiﬁ  cantly 
greater with higher dose statin therapy vs. lower dose 
therapy (1.4% vs. 0.4%, p   0.0001) (Josan et al 2007). 
In contrast, the frequency of elevated transaminases in the 
Table 1 statin placebo-controlled trials was 1.2% in 33,465 
placebo-treated patients and 1.6% in 33,494 statin-treated 
patients (p = 0.0001). Myopathic adverse events were incon-
sistently reported in these trials and in the placebo-controlled 
statin trials. While the A-to-Z trial reported a small but 
statistically signiﬁ  cant increase in cases of rhabdomyolysis 
among the patients receiving higher dose statin therapy 
(0.4% vs 0.04%, p = 0.02), neither the IDEAL (0.05% vs 
0.07%, p = 0.99) nor TNT (0.04% vs 0.06%, p = 0.99) trials 
found any signiﬁ  cant difference in rhabdomyolysis risk. The 
pooled frequency of statin-associated myopathy (as per the 
American College of Cardiology/American Heart Associa-
tion deﬁ  nition, myopathy covers any muscle complaints, with 
or without elevated CK levels) (Pasternak et al 2002) was 
3.3% in patients randomized to higher dose statins and 2.8% 
in patients randomized to lower dose statins (p = 0.008); in 
comparison, the rates were 0.9% in 34,830 placebo-treated 
patients and 0.9% in 34,848 statin-treated patients in the 
Table 1 trials (p = 0.89).
Discussion 
The expected relative risk reductions associated with lower 
dose statin regimens over placebo are 23% for myocardial 
infarction, 17% for stroke, and 13% for all-cause mortality 
(Cholesterol Treatment Trialists 2005). Compared to lower 
dose statin therapy, higher dose statin therapy reduces myo-
cardial infarctions by a further 16% and strokes by 18% in 
patients with CAD – both of these values are relative risk 
reductions and the absolute beneﬁ  ts depend on the baseline 
risk of the patients in which these drugs are used. Although 
there is no appreciable effect on survival in patients with 
chronic CAD, in those patients at higher risk for death due to 
recent acute coronary syndromes higher dose statin therapy 
does confer an additional 25% relative reduction in all-cause 
mortality over and above the reductions expected with low 
dose statin therapy. Higher dose statin regimens are also 
associated with statistically signiﬁ  cantly increased risks of 
myopathy, elevated transaminases, and drug discontinuation 
compared to lower dose statins. However, although relative 
risks for these outcomes range from 1.2 to 4.0, the absolute 
increases are small (particularly when balanced against the 
absolute reductions of 1.6% in myocardial infarction and 
0.5% in stroke seen in the trials reviewed above). 
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Introduction
The first female-specific recommendations for preventive cardiology were published in
1999 (Mosca et al 1999). Even though research in the treatment of cardiovascular disease
(CVD) had advanced in many areas, it remains the leading cause of death in women in
most parts of the world. Studies have shown that 500 thousand women die of CVD every
year in the United States, somewhat near one death every minute (American Heart
Association 2003). Such index exceeds not only the number of deaths in men, but also the
next seven causes of death in women combined, and more importantly, coronary artery
disease (CAD) is believed to be the major cause responsible for these deaths (American
Heart Association 2003). Over a quarter of a million deaths per year are attributed to CAD
alone in the United States (Merz et al 2004). Although already high, these figures are
expected to rise even more during the next decades, due to an increase of diabetes and
obesity, as well as the aging of the world population (Merz et al 2004).
Even though women have a higher frequency of chest pain/angina than men, the
incidence of obstructive CAD in the female population is lower when compared with
men with similar symptoms (Kenedy et al 1982; Diamond et al 1983; Merz et al 1999). In
addition, it would appear that young women with obstructive CAD have a worse
prognosis after acute myocardial infarction (AMI), whereas older women in similar
circumstances often present with larger number of comorbidities that adversely influence
the outcome, when compared to men (Coronado et al 1997). Women with acute coronary
syndromes (ACS) are also less likely to receive rapid effective diagnosis and treatment
than are men (Ayanian and Epstein 1991; Maynard et al 1996; Pope
et al 2000).
Regarding the North American population, the Women’s Ischemic Syndrome
Evaluation (WISE) study workshop (Hayes et al 2004; Maseri 2004; Nabel et al 2004;
Pepine et al 2004; Shaw et al 2004; Waters et al 2004) from the National Heart, Lung and
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However, there are two caveats to our ﬁ  ndings. First, 
although the current literature supports the use of higher dose 
statin regimens in patients with established CAD, it provides 
limited insight into whether high or low dose statins should 
be employed in patients without CAD but with elevated 
cholesterols and/or multiple atherosclerotic risk factors. 
Although the ASAP and ARBITER Trials have shown that 
higher dose statin therapy does reduce the surrogate outcome 
of progression in carotid intima media thickness in patients 
with familial hypercholesterolemia (Smilde et al 2001) or 
a wide variety of conditions which placed them at risk for 
atherosclerosis (Taylor et al 2002), the number of clinically 
apparent events (ie, MI, stroke, or death) was far too few in 
these trials to make deﬁ  nitive conclusions at this time. We 
do not believe that the secondary prevention trials that we 
reviewed can be generalized to patients without coronary 
disease and this is an area that should be a research priority 
(particularly given a recent secondary analysis of TNT sug-
gesting that patients with metabolic syndrome may derive 
even greater beneﬁ  ts from higher dose statin therapy than 
other patients (Deedwania et al 2006).
Second, although our analysis provides information on 
the beneﬁ  ts and safety of higher dose versus lower dose 
statin therapy, none of these trials provide data which can 
directly answer the question of optimal LDL targets as 
none provide a breakdown of event rates by LDL achieved. 
Although patients randomized to lower dose statins in the 
dose comparison trials we reviewed had higher event rates, 
it is possible that only a subset of the patients in the random-
ized arms contributed to the difference. That is, the worse 
outcomes in the lower dose statin group may be the result 
of events occurring in those patients with persisting LDL 
elevations rather than a result of the mean LDL achieved 
not being low enough (Mann 2006). As previously men-
tioned, multidrug therapy is frequently required to achieve 
lower LDL targets thus resulting in increased risk of adverse 
effects and/or patient non-adherence to prescribed therapy. 
Although short-term trials with LDL cholesterol endpoints 
have demonstrated that non-statin agents can further lower 
LDL cholesterol when added to statin therapy (Brown et al 
2001; Stein et al 2004; Bissonette et al 2006), there is cur-
rently a paucity of long-term trials proving that these agents 
provide further reductions in clinical outcomes (such as 
myocardial infarction, stroke, or death) above those achieved 
with statin therapy alone. 
Without individual patient data we cannot calculate 
risk reductions per mmol/L reduction in LDL cholesterol 
but extrapolating from the expected beneﬁ  ts based on the 
Cholesterol Treatment Trialists’ Collaboration suggests 
that the beneﬁ  ts seen in these trials are generally consistent 
with what would have been expected given the mean LDL 
reduction observed in these trials (0.61 mmol/L) and their 
relatively long duration. This latter point is relevant since 
the placebo-controlled statin trials demonstrated that the 
beneﬁ  ts of statins are approximately half as large in the ﬁ  rst 
year of use as in subsequent years (Cholesterol Treatment 
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Introduction
The first female-specific recommendations for preventive cardiology were published in
1999 (Mosca et al 1999). Even though research in the treatment of cardiovascular disease
(CVD) had advanced in many areas, it remains the leading cause of death in women in
most parts of the world. Studies have shown that 500 thousand women die of CVD every
year in the United States, somewhat near one death every minute (American Heart
Association 2003). Such index exceeds not only the number of deaths in men, but also the
next seven causes of death in women combined, and more importantly, coronary artery
disease (CAD) is believed to be the major cause responsible for these deaths (American
Heart Association 2003). Over a quarter of a million deaths per year are attributed to CAD
alone in the United States (Merz et al 2004). Although already high, these figures are
expected to rise even more during the next decades, due to an increase of diabetes and
obesity, as well as the aging of the world population (Merz et al 2004).
Even though women have a higher frequency of chest pain/angina than men, the
incidence of obstructive CAD in the female population is lower when compared with
men with similar symptoms (Kenedy et al 1982; Diamond et al 1983; Merz et al 1999). In
addition, it would appear that young women with obstructive CAD have a worse
prognosis after acute myocardial infarction (AMI), whereas older women in similar
circumstances often present with larger number of comorbidities that adversely influence
the outcome, when compared to men (Coronado et al 1997). Women with acute coronary
syndromes (ACS) are also less likely to receive rapid effective diagnosis and treatment
than are men (Ayanian and Epstein 1991; Maynard et al 1996; Pope
et al 2000).
Regarding the North American population, the Women’s Ischemic Syndrome
Evaluation (WISE) study workshop (Hayes et al 2004; Maseri 2004; Nabel et al 2004;
Pepine et al 2004; Shaw et al 2004; Waters et al 2004) from the National Heart, Lung and
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Trialists’ Collaboration 2005). Although the general consis-
tency of the clinical event reductions for the observed LDL 
reductions lends support to those asserting that the lower the 
LDL the better (O’Keefe et al 2004), it does not provide any 
information about whether there is a lower threshold below 
which further reduction in LDL cholesterol is not helpful (or 
is even harmful). Indeed, it could be argued that although the 
data from the 7 intensive therapy trials is generally consistent 
with that from the placebo-controlled trials, the clinical event 
reduction seen in these trials is slightly lower than would be 
expected for trials of such long duration. Thus, although 
it is commonly asserted that for every 1% reduction in 
LDL levels, the relative risk for major coronary events 
is reduced by approximately 1% (Grundy 2004), all 4 of 
the intensive therapy trials that reported data on major 
coronary events failed to show such a relationship. For 
example, although LDL levels were reduced by 35% in 
PROVE IT, this was associated with only a 16% relative 
risk reduction in major coronary events and although LDL 
levels were reduced by 22% in IDEAL the major coronary 
event rate was only reduced by 11%. While the current 
literature is inadequate to assess whether there may be an 
LDL threshold below which further reductions in LDL 
do not improve clinical outcomes, such a study could be 
done with the trial data at hand if a cohort analysis to 
explore the association between LDL levels and clinical 
outcomes was conducted with multivariate adjustment for 
prescribed therapies (statins and concomitant anti-athero-
sclerotic therapies), adherence, and changes in other risk 
factors as well as baseline imbalances in prognostic risk 
factors (Hayward et al 2006).
Although the Cholesterol Treatment Trialists suggested 
that there was an approximately linear relationship between 
the LDL cholesterol achieved and the reductions in clinical 
outcomes, the mean pre-treatment LDL cholesterol of 
3.79 mmol/L in their meta-analysis is considerably higher 
than that of patients in the higher vs. lower dose statin trials 
reviewed in this manuscript. As a result, there were undoubt-
edly fewer patients that had baseline LDLs lower than 2.59 
mmol/L in the placebo-controlled trials. Indeed, while several 
of the placebo-controlled trials did examine whether patients 
with lower baseline LDL levels derived the same beneﬁ  ts 
from LDL reduction as those starting from higher LDL levels, 
the results were mixed. For example, while the CARE trial 
(Sacks et al 1996) demonstrated no beneﬁ  t with statin therapy 
in patients with baseline LDL level  3.2 mmol/L (22% rate 
of major coronary events vs 21% in placebo-treated patients) 
and the LIPID trial (LIPID study group 1998) reported less 
beneﬁ  t with statins in patients with baseline LDL   3.5 
mmol/L (mortality relative risk reduction 16% vs 30% beneﬁ  t 
in those patients with higher baseline LDL levels), the Heart 
Protection Study (MRC/BHF 2002), PROSPER (Shepherd 
et al 2002), CARDS (Colhoun et al 2004), and MIRACL 
(Schwartz et al 2001) trials all demonstrated similar beneﬁ  ts 
across subgroups regardless of baseline LDL level. 
Although they are most effective at decreasing LDL 
levels, statins are also known to exert varying effects on 
triglyceride and HDL levels (Jones 2003) and statins do 
differ in their non-cholesterol pleiotropic effects (Davignon 
2004). However, as the trials comparing more intensive vs 
less intensive statin therapy do not consistently report post 
treatment triglyceride and HDL levels or non-cholesterol risk 
factors (such as C-reactive protein) one cannot determine the 
contribution of these factors. As a result, we believe there is 
currently no evidence to support assertions that a higher dose 
of one statin is more efﬁ  cacious than higher doses of any other 
statin (assuming equipotent dosing and equal reductions in 
LDL cholesterol) for clinical outcomes.
In considering the beneﬁ  ts of lipid lowering with higher 
dose statin therapy, one must also weigh the potential harms 
to the patient. After all, cholesterol is a cell membrane 
component and plays a key role in vitamin synthesis. While 
ecological and cohort data did raise concerns that very low 
cholesterol levels may be associated with increases in non-
cardiovascular mortality, intracranial hemorrhage, cancer, or 
suicide, these concerns have been proven unfounded by the 
randomized trial literature (and likely reﬂ  ected the fact that 
systemic illnesses which predisposed to those outcomes also 
lowered cholesterol levels). Indeed, a recent meta-analysis 
of 35 randomized placebo-controlled statin trials (with data 
on over 74,000 patients followed for a mean of 17 months) 
documented that there was no appreciable increase in the 
risk of myalgias, CK elevations, rhabdomyolysis, or drug 
discontinuation with non-cerivastatin statins over placebo-
treated patients, and although the risk of transaminase 
elevations was higher with statin treatment, the absolute risk 
was only 4 cases per 1000 patients (Kashani 2006). In our 
analysis of trials comparing different doses of statins (none 
of which were included in the aforementioned meta-analysis), 
we found that although adverse event rates (particularly 
myopathy and hepatotoxicity) were higher with higher dose 
statin therapy than with lower dose therapy, the absolute 
rates of adverse events were low in these trials (and in the 
placebo-controlled statin trials). Further, post-hoc analyses 
suggest that adverse events are not related to achieved LDL 
cholesterol levels (Wiviott 2005). Vascular Health and Risk Management 2006:2(4) 465–475
© 2006 Dove Medical Press Limited. All rights reserved
465
REVIEW
Leila Fernandes Araujo
Alexandre de Matos Soeiro
Juliano Lara Fernandes
Antônio Eduardo Pesaro
Carlos V Serrano Jr
Heart Institute (InCor), University
of São Paulo, School of Medicine,
Brazil
Correspondence: Carlos V Serrano Jr
Coronary Care Unit, Av. Dr. Enéas
Carvalho Aguiar, 44 – sala 12 – bloco 2,
São Paulo - SP - 05403-900, Brazil
Tel +55 11 3069 5058
Fax +55 11 3088 3809
Email carlos.serrano@incor.usp.br
Abstract: Despite numerous studies on women’s cardiac health throughout the past decade, the
number of female deaths caused by cardiovascular disease still rises and remains the leading cause
of death in women in most areas of the world. Novel studies have demonstrated that cardiovascular
disease, and more specifically coronary artery disease presentations in women, are different than
those in men. In addition, pathology and pathophysiology of the disease present significant
gender differences, which leads to difficulties concerning diagnosis, treatment and outcome of the
female population. The reason for this disparity is all steps for female cardiovascular disease
evaluation, treatment and prevention are not well elucidated; and an area for future research. This
review brings together the most recent studies published in the field of coronary artery disease
in women and points out new directions for future investigation on some of the important issues.
Keywords: coronary artery disease, women, risk factors, prevention, diagnosis, treatment.
Introduction
The first female-specific recommendations for preventive cardiology were published in
1999 (Mosca et al 1999). Even though research in the treatment of cardiovascular disease
(CVD) had advanced in many areas, it remains the leading cause of death in women in
most parts of the world. Studies have shown that 500 thousand women die of CVD every
year in the United States, somewhat near one death every minute (American Heart
Association 2003). Such index exceeds not only the number of deaths in men, but also the
next seven causes of death in women combined, and more importantly, coronary artery
disease (CAD) is believed to be the major cause responsible for these deaths (American
Heart Association 2003). Over a quarter of a million deaths per year are attributed to CAD
alone in the United States (Merz et al 2004). Although already high, these figures are
expected to rise even more during the next decades, due to an increase of diabetes and
obesity, as well as the aging of the world population (Merz et al 2004).
Even though women have a higher frequency of chest pain/angina than men, the
incidence of obstructive CAD in the female population is lower when compared with
men with similar symptoms (Kenedy et al 1982; Diamond et al 1983; Merz et al 1999). In
addition, it would appear that young women with obstructive CAD have a worse
prognosis after acute myocardial infarction (AMI), whereas older women in similar
circumstances often present with larger number of comorbidities that adversely influence
the outcome, when compared to men (Coronado et al 1997). Women with acute coronary
syndromes (ACS) are also less likely to receive rapid effective diagnosis and treatment
than are men (Ayanian and Epstein 1991; Maynard et al 1996; Pope
et al 2000).
Regarding the North American population, the Women’s Ischemic Syndrome
Evaluation (WISE) study workshop (Hayes et al 2004; Maseri 2004; Nabel et al 2004;
Pepine et al 2004; Shaw et al 2004; Waters et al 2004) from the National Heart, Lung and
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However, it should be acknowledged that adverse 
events may be more common in clinical practice since trial 
participants tend to be healthier and more closely followed 
than usual patients. Indeed, these trials excluded over half 
of all patients screened because of various factors known 
to increase the risk of adverse events: advanced age, renal 
failure, hepatic failure, hypothyroidism, or concomitant use 
of ﬁ  brates, macrolide antibiotics, antifungal agents, HIV 
protease inhibitors, verapamil, or cyclosporine (Grundy 
2005). Having raised this objection, however, it should be 
acknowledged that adverse events with statin therapy appear 
to be relatively similar when used in the non-trial setting as 
in the randomized trials, at least based on analyses of large 
cohort studies, administrative databases, and FDA reports 
published so far (Thompson et al 2003; Bays 2005; Charles 
2005). However, the relatively short time frame of the ran-
domized trials of higher dose vs. lower dose statin therapy 
conducted thus far should be acknowledged and emphasizes 
the importance of post-marketing surveillance to track 
complication rates over longer time periods, and in larger 
samples (witness the problems with cerivastatin which only 
became apparent when scores of thousands of patients had 
been prescribed the drug in North America). The ongoing 
SEARCH (Study of the Effectiveness of Additional Reduc-
tions in Cholesterol and Homocysteine) Trial will provide 
much needed safety information on high dose statin therapy 
(simvastatin 80 mg daily vs. 20 mg daily) over a longer time-
frame (12,064 study participants, with an expected average 
follow-up of 7 years).
In addition to the adverse events attributed to statin 
use, attention should be drawn to the overall discontinu-
ation rate with higher dose vs. lower dose statin therapy 
which likely reflects adverse effects such as nausea, diar-
rhea, and abdominal pain. These symptoms are typically 
dismissed as nuisance effects rather than true adverse 
events and thus not systematically captured in randomized 
trial case reports. However, if such nuisance effects lead 
patients to discontinue potentially life saving drugs, they 
are clearly important contributors to patient outcomes. 
Thus, the argument could be made that in those intoler-
ant to higher dose statin therapy, it may be beneficial to 
derive some benefit from a low dose statin than no benefit 
from a discontinued high dose statin.
In closing, the current literature does prove conclusively 
that higher dose statin therapy (for example, 80 mg of sim-
vastatin or atorvastatin) in patients with established CAD 
provides incremental beneﬁ  ts over and above those expected 
with lower dose statin therapy; however, this literature is 
insufﬁ  cient to deﬁ  ne optimal LDL targets in these patients. 
Secondary analyses of the existing randomized trial data 
using individual patient data and multivariate adjustment will 
be needed to appropriately examine the incremental beneﬁ  ts 
of different LDL targets (Hayward 2006), and future trials 
will have to determine whether lower dose statin therapy plus 
other lipid lowering agents may achieve better LDL levels 
and clinical outcomes than maximal dose statin therapy. 
Indeed, further research is needed to conclusively establish 
whether the beneﬁ  ts associated with statin treatment are 
determined by the LDL level achieved, the percent reduc-
tion in LDL, the absolute reduction in LDL, or the dose of 
the statin. Based on the current evidence base, the use of 
higher dose statin therapy should be restricted to patients 
with established CAD at this time. 
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Introduction
The first female-specific recommendations for preventive cardiology were published in
1999 (Mosca et al 1999). Even though research in the treatment of cardiovascular disease
(CVD) had advanced in many areas, it remains the leading cause of death in women in
most parts of the world. Studies have shown that 500 thousand women die of CVD every
year in the United States, somewhat near one death every minute (American Heart
Association 2003). Such index exceeds not only the number of deaths in men, but also the
next seven causes of death in women combined, and more importantly, coronary artery
disease (CAD) is believed to be the major cause responsible for these deaths (American
Heart Association 2003). Over a quarter of a million deaths per year are attributed to CAD
alone in the United States (Merz et al 2004). Although already high, these figures are
expected to rise even more during the next decades, due to an increase of diabetes and
obesity, as well as the aging of the world population (Merz et al 2004).
Even though women have a higher frequency of chest pain/angina than men, the
incidence of obstructive CAD in the female population is lower when compared with
men with similar symptoms (Kenedy et al 1982; Diamond et al 1983; Merz et al 1999). In
addition, it would appear that young women with obstructive CAD have a worse
prognosis after acute myocardial infarction (AMI), whereas older women in similar
circumstances often present with larger number of comorbidities that adversely influence
the outcome, when compared to men (Coronado et al 1997). Women with acute coronary
syndromes (ACS) are also less likely to receive rapid effective diagnosis and treatment
than are men (Ayanian and Epstein 1991; Maynard et al 1996; Pope
et al 2000).
Regarding the North American population, the Women’s Ischemic Syndrome
Evaluation (WISE) study workshop (Hayes et al 2004; Maseri 2004; Nabel et al 2004;
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Abstract: Despite numerous studies on women’s cardiac health throughout the past decade, the
number of female deaths caused by cardiovascular disease still rises and remains the leading cause
of death in women in most areas of the world. Novel studies have demonstrated that cardiovascular
disease, and more specifically coronary artery disease presentations in women, are different than
those in men. In addition, pathology and pathophysiology of the disease present significant
gender differences, which leads to difficulties concerning diagnosis, treatment and outcome of the
female population. The reason for this disparity is all steps for female cardiovascular disease
evaluation, treatment and prevention are not well elucidated; and an area for future research. This
review brings together the most recent studies published in the field of coronary artery disease
in women and points out new directions for future investigation on some of the important issues.
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Introduction
The first female-specific recommendations for preventive cardiology were published in
1999 (Mosca et al 1999). Even though research in the treatment of cardiovascular disease
(CVD) had advanced in many areas, it remains the leading cause of death in women in
most parts of the world. Studies have shown that 500 thousand women die of CVD every
year in the United States, somewhat near one death every minute (American Heart
Association 2003). Such index exceeds not only the number of deaths in men, but also the
next seven causes of death in women combined, and more importantly, coronary artery
disease (CAD) is believed to be the major cause responsible for these deaths (American
Heart Association 2003). Over a quarter of a million deaths per year are attributed to CAD
alone in the United States (Merz et al 2004). Although already high, these figures are
expected to rise even more during the next decades, due to an increase of diabetes and
obesity, as well as the aging of the world population (Merz et al 2004).
Even though women have a higher frequency of chest pain/angina than men, the
incidence of obstructive CAD in the female population is lower when compared with
men with similar symptoms (Kenedy et al 1982; Diamond et al 1983; Merz et al 1999). In
addition, it would appear that young women with obstructive CAD have a worse
prognosis after acute myocardial infarction (AMI), whereas older women in similar
circumstances often present with larger number of comorbidities that adversely influence
the outcome, when compared to men (Coronado et al 1997). Women with acute coronary
syndromes (ACS) are also less likely to receive rapid effective diagnosis and treatment
than are men (Ayanian and Epstein 1991; Maynard et al 1996; Pope
et al 2000).
Regarding the North American population, the Women’s Ischemic Syndrome
Evaluation (WISE) study workshop (Hayes et al 2004; Maseri 2004; Nabel et al 2004;
Pepine et al 2004; Shaw et al 2004; Waters et al 2004) from the National Heart, Lung and
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